Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Notes Payables (2020 - 2023)

Firefly Neuroscience has reported Notes Payables over the past 3 years, most recently at $94071.0 for Q3 2023.

  • Quarterly results put Notes Payables at $94071.0 for Q3 2023, changed N/A from a year ago — trailing twelve months through Sep 2023 was $94071.0 (changed N/A YoY), and the annual figure for FY2020 was $93009.0, changed.
  • Notes Payables for Q3 2023 was $94071.0 at Firefly Neuroscience, down from $186115.0 in the prior quarter.
  • Over the last five years, Notes Payables for AIFF hit a ceiling of $1.5 million in Q2 2021 and a floor of $37157.0 in Q3 2020.
  • Median Notes Payables over the past 3 years was $149002.0 (2020), compared with a mean of $366498.9.
  • Peak annual rise in Notes Payables hit 2045.75% in 2021, while the deepest fall reached 917.88% in 2021.
  • Firefly Neuroscience's Notes Payables stood at $93009.0 in 2020, then skyrocketed by 757.22% to $797295.0 in 2021, then crashed by 88.2% to $94071.0 in 2023.
  • The last three reported values for Notes Payables were $94071.0 (Q3 2023), $186115.0 (Q2 2023), and $276173.0 (Q1 2023) per Business Quant data.